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The linked Mrf4 and Myf5 genes encode two transcription factors essential for the determination and
differentiation of skeletal muscle in the embryo. The locus is controlled by a multitude of interdigitated
enhancers that activate gene expression at different times and in precisely defined progenitor cell populations.
Manipulation of the enhancer–promoter composition of the locus reveals a novel mechanism for the
regulation of such a gene cluster. Enhancers, promoters, and a new class of elements we call transcription
balancing sequences, which can act as cryptic promoters, exist in a series of equilibria to ensure that
enhancers and promoters together produce the highly dynamic and exquisitely specific expression patterns of
the two genes. The proposed model depends upon nonproductive interactions between enhancers and both
minimal and cryptic promoters, and is distinct from those developed for the !-globin and Hox clusters.
Moreover, it provides an explanation for the unexpected phenotypes of the three Mrf4 knockout alleles.
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Eukaryotes employ diverse mechanisms to control gene
expression that can be categorized into transcriptional,
post-transcriptional, and post-translational regulation.
Of these, the rate of transcriptional initiation is probably
the most important factor controlling the overall ex-
pression pattern of a gene. Basal promoters can initiate
transcription on their own, but since most of the tran-
scription factor-binding sites within them interact with
ubiquitously expressed factors, transcription is not tis-
sue-specific, and is usually driven at low levels. To in-
crease transcription rates, and to confer specificity, en-
hancers interact with basal promoters by means that are
not fully understood; the specificity is determined by the
combination of binding sites in their sequences. In con-
trast, throughout mammalian genomes many cryptic
promoters have been identified, sequences only able to
initiate transcription following an alteration of their ge-
nomic environment, either experimentally or as the re-
sult of a translocation. These cryptic promoters must be
prevented from interacting productively with the en-
hancers so that they remain transcriptionally silent. The
expression pattern of any particular gene is established
by the promoter/enhancer composition of the locus, the
availability of cognate transcription factors, and the ki-
netics and mechanics affecting their interactions. The
maintenance of the correct specificity of these interac-
tions is crucial for orderly development and differentia-
tion, and is a particular problem in loci containing mul-
tiple genes related by function and/or expression pattern.
Of significant interest in this context is the regulation of
genes encoding transcription factors that play key roles
in a cascade controlling cell fate decisions.
During mouse embryogenesis, skeletal muscle arises
from three different locations: segmented somitic par-
axial mesoderm, unsegmented paraxial head mesoderm,
and prechordal mesoderm. Trunk and limb muscles
originate from the somitic epithelial dermomyotome (for
review, see Kalcheim and Ben-Yair 2005). Progenitor
cells delaminate from the four lips of the dermomyo-
tome and move into the myotome, in which they de-
velop in situ or subsequently travel to their final desti-
nation. At limb levels, cells from the ventrolateral lip
(VLL) of the dermomyotome migrate into the developing
limb buds, to form the appendicular musculature, while
at more rostral positions VLL cells delaminate and fol-
low a long-range migration along the hypoglossal chord
to give rise to pharyngeal and tongue musculature. Facial
musculature is derived from unsegmented head meso-
derm and prechordal mesoderm cells, which either move
through the branchial arches or directly to their final
destination (for review, see Noden and Francis-West
2006).
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In all of these locations the determination, migration,
and terminal differentiation of skeletal muscle cells are
controlled by a network in which the four myogenic
regulatory factors (MRFs)—Myf5, Mrf4, MyoD, andmyo-
genin—play key roles. Myf5 and MyoD can act as deter-
mination genes, while myogenin is essential for the ter-
minal differentiation of committed myoblasts (for re-
view, see Berkes and Tapscott 2005). Mrf4 has long been
considered a differentiation gene, but it is expressed in
undifferentiated cells and can act as a determination
gene (Kassar-Duchossoy et al. 2004)
We have focused on the transcriptional regulation of
Mrf4 and Myf5, which are separated by 8.7 kb in the
mouse and are linked in all vertebrates. Myf5 is the first
MRF gene expressed in the mouse; it is activated before
8.5 d post-coitum (dpc) in the dorsomedial lip of the so-
mite and then extends into the newly formed myotome;
by 9.5 dpc, expression begins in the ventral dermomyo-
tome and branchial arches. As limbs develop, Myf5 is
up-regulated in the central premuscle mass but not in
migrating progenitors (Ott et al. 1991; Summerbell et al.
2000). During myoblast fusion expression is maintained
in all skeletal muscle masses but it is down-regulated
from late gestation, and only quiescent satellite cells and
muscle spindles retain expression in the adult (Zammit
et al. 2004).Mrf4 expression closely follows that ofMyf5
but is triphasic. It begins in undifferentiated cells of the
ventral somite coincident with the onset ofMyf5 expres-
sion in the dorsomedial lip (Carvajal et al. 2001; Sum-
merbell et al. 2002). It is then activated in the central
myotome of rostral somites at ∼9.0 dpc, and by 10.0 dpc
includes all somites but is absent from the limbs and
branchial arch derivatives. This phase is down-regulated
in a rostrocaudal direction in all somites from 12.5 dpc,
followed by a third phase in which expression is up-regu-
lated and maintained in all skeletal muscles in the adult.
The regulation of linked and functionally related genes
has been studied in a number of systems. In the !-globin
locus temporal switching from one gene to another in
the same cell type is regulated by proximal sequences,
insulators restrict interactions, while overall levels of
expression are controlled by the distal locus control re-
gion (LCR), involved in chromatin architecture (for re-
view, see de Laat and Grosveld 2003). In vertebrate Hox
clusters global control regions regulate the expression of
multiple genes, and locally acting elements shared be-
tween adjacent genes affect expression in particular cell
types and tissues (Spitz et al. 2003). In Drosophila
homeotic clusters, the precise structure of core promoter
elements controls enhancer–promoter selectivity while
a novel class of element (promoter tethers) facilitates
interactions of enhancers with core promoters (Calhoun
and Levine 2003).
Transcriptional regulation of Myf5 has been studied
extensively in transgenic mice (Patapoutian et al. 1993;
Zweigerdt et al. 1997; Hadchouel et al. 2000, 2003; Sum-
merbell et al. 2000; Carvajal et al. 2001; Teboul et al.
2002; Buchberger et al. 2003; Zammit et al. 2004). A
similar approach has been used in the analysis of the
transcriptional regulation of Mrf4 (Patapoutian et al.
1993; Pin et al. 1997; Carvajal et al. 2001; Pin and Ko-
nieczny 2002). We have shown previously that a 250-kb
BAC clone carrying 195 kb of sequence upstream of the
Myf5 translational start site (BAC195) is able to fully
recapitulate the expression patterns of both Mrf4 and
Myf5 during embryonic development (Carvajal et al.
2001) and in the adult (Zammit et al. 2004). A complex
picture has emerged (Fig. 1A) in which a multitude of
enhancers regulate the activation of Myf5 at different
times and anatomical locations during development,
suggesting that the inductive signals for myogenesis are
diverse, and that Myf5 may function to canalize these
Figure 1. Maps of the regulatory elements in the Mrf4/Myf5
locus and of the constructs generated for the study of global
regulation. (A) Schematic representation of the regions involved
in the transcriptional regulation of the Mrf4/Myf5 locus. Each
colored box represents transcription occurring at either differ-
ent times or anatomical locations in embryonic or adult skeletal
muscle. The color key is included below the map. (B) Schematic
representation of construct B195APZWT, showing the location
of the reporter genes (red box, human placental alkaline phos-
phatase gene [PLAP]; dark blue box, nuclear localized lacZ gene
[nlacZ]); the EEE, PAE, and CNSE (pale blue, green, and orange
boxes, respectively); the minimal promoters (yellow boxes); and
the end points of the BAC clone. (C–H) Schematic representa-
tion of the different modifications introduced into B195APZ,
and the number of independent transgenic lines and individual
transient embryos analyzed (in brackets). (MP5) Myf5 minimal
promoter; (MP4) Mrf4 minimal promoter.
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signals into a single skeletal muscle fate. Mrf4 is also
differentially regulated in time and space, but the num-
ber of regulatory sequences involved is more limited
(Carvajal et al. 2001). Themajority ofMyf5 enhancers are
upstream of Mrf4 elements and closer to the Mrf4 pro-
moter than to that of Myf5, and most are located in in-
trons of the adjacent PTPRQ gene (Fig. 1A), which is not
expressed in skeletal muscle precursors. The locus thus
provides an ideal system to investigate the mechanisms
by which enhancer–promoter specificity is controlled so
as to precisely regulate the rapidly changing and exquis-
itely precise expression patterns of these determination
genes.
We propose the existence of a novel mechanism for the
global transcriptional control of complex loci that de-
pends on the maintenance of a series of equilibria be-
tween enhancers and promoters that are revealed by
modification of the regulatory elements within the lo-
cus. Crucial to the establishment and fine tuning of the
different equilibrium states are intergenic sequences
that can initiate transcription when the locus is per-
turbed and can interact positively or negatively with the
enhancers. Because of their activity, we term these ele-
ments transcription balancing sequences (TRABS).
Results
Deletion of the Myf5 minimal promoter allows some
Myf5-specific elements to interact with the Mrf4
promoter
InDrosophila promoter–enhancer specificity can depend
on the precise sequence of the TATA box (Ohtsuki et al.
1998; Butler and Kadonaga 2001). A putative TATA box
is located between 183 and 177 base pairs (bp) upstream
of the translational start site of Myf5. To identify the
transcriptional start site we carried out 5!-rapid amplifi-
cation of cDNA ends (RACE) amplification of total RNA
from nontransgenic embryos and obtained a single am-
plification fragment. Multiple independent clones were
sequenced that localized the transcriptional initiation
site 155 bp upstream of the ATG, indicating that the
putative TATA box is likely to be functional (data not
shown).
We investigated whether the TATA box contributes to
enhancer–promoter selectivity by mutating this element
(TATATAA to aAaAaAA) in the context of BAC195APZ
(constructs B195APZwt, B195APZmTATA-5) (Fig. 1B,C, re-
spectively), which can fully recapitulate the expression
patterns of Mrf4 and Myf5 (Carvajal et al. 2001). In
B195APZmTATA-5 embryos these patterns were identical
to those in B195APZwt embryos (data not shown).
Since the TATA box is not required for correct en-
hancer–promoter specificity in this locus, we inves-
tigated the effects of deleting the entire Myf5 mini-
mal promoter (as functionally defined by Summerbell
et al. 2000; see Supplemental Fig. 1) to generate
B195APZ!MP5 (Fig. 1D). The timing and pattern of ex-
pression of AP-Mrf4 is normal at 9.25 and 9.5 dpc (Fig.
2A,B) but then rapidly changes, incorporating aspects of
the Myf5 pattern. At 10.5 dpc AP-Mrf4 expression is de-
tected in both fore- and hindlimbs (Fig. 2C,D, respec-
tively), 48 h earlier than endogenous Mrf4. At 11.0 dpc
AP-Mrf4 is expressed in the brain (Fig. 2E), and is main-
tained in the limb buds and expressed weakly in the
branchial arches (data not shown). The cells in the limbs
and the arches in which this AP-Mrf4 expression is seen
do not, at these times, expressmyogenin (Yee and Rigby
1993) and thus have not entered the terminal differen-
tiation program. By 11.5 dpc, expression is still visible in
the limb buds (Fig. 2F), and at 12.5 dpc (Fig. 2G), and later
(data not shown), weak AP-Mrf4 expression is clearly
seen in derivatives of the mandibular and hyoid arches,
Figure 2. In the absence of the Myf5 minimal promoter, some
Myf5-specific enhancers drive AP-Mrf4 expression. In the ab-
sence of the Myf5 minimal promoter, expression of AP-Mrf4 at
9.25 dpc (A) and 9.5 dpc (B) is indistinguishable from that of the
wild type. At 10.5 dpc, AP-Mrf4 is expressed in forelimbs (C,
black arrowhead) and hindlimbs (D, black arrowhead). (E) At
11.0 dpc,AP-Mrf4 is expressed inMyf5-specific domains such as
the brain (black arrowhead). (F) By 11.5 dpc, AP-Mrf4 expression
is maintained in the limb buds, but is stronger in the hindlimb
(black arrowhead). (G) By 12.0 dpc, AP-Mrf4 expression is acti-
vated in derivatives of the mandibular and hyoid arches (black
and white arrowheads, respectively). (H) In the control embryo,
carrying construct B195APZWT, AP-Mrf4 is not detected at
these sites.
Transcription balancing sequences
GENES & DEVELOPMENT 267
which are normally Myf5 but not Mrf4 expression do-
mains. Thus, in the absence of the Myf5 minimal pro-
moter, Myf5-specific elements are able to activate the
remaining promoter, addingMyf5 expression domains to
the normal pattern of Mrf4 (which is shown in Fig. 2H;
also shown in Fig. 6 of Carvajal et al. 2001). It thus might
appear that straightforward promoter competition oper-
ates for some enhancers; e.g., those functioning in the
limbs, brain, and branchial arches. Their productive en-
gagement is always with the Myf5 promoter but in its
absence they engage with the Mrf4 promoter to direct
transcription that is temporally and spatially correct for
Myf5. However, it is particularly interesting to note that
the early epaxial enhancer (EEE), which drives the earli-
est expression of Myf5 in the dorsomedial lip of the so-
mite (Summerbell et al. 2000; Teboul et al. 2002), is not
able to engage the Mrf4 promoter even in this context
(Fig. 2A,B), indicating that enhancer–promoter specific-
ity in this locus is controlled by a different mechanism.
Myf5 expression is not abolished in the absence
of its minimal promoter
To confirm that deletion of the minimal promoter abol-
ishes nlacZ-Myf5 expression, we analyzed B195APZ!MP5
embryos for "-galactosidase activity. Expression is com-
pletely abolished at 8.5 dpc but, surprisingly, weakMyf5
expression is observed by 9.5 dpc in branchial arches and
the caudal edges of the somites (Fig. 3A). By 10.5 dpc the
intensity of expression is greatly increased and it is
readily visible in arches, limb buds, and both rostral and
caudal somitic edges, while still absent from the dorso-
medial lip of the somite, the myotome, and the ventral
somitic bud (Fig. 3B). At later stages, the expression pat-
tern becomes virtually indistinguishable from that
driven by the wild-type B195APZ (see Carvajal et al.
2001), except for the dorsomedial lip (Fig. 3C, 11.5 dpc)
and the tail somites (Fig. 3D, 12.5 dpc) where it is miss-
ing. By 13.5 dpc the only difference from wild type is the
missing expression in tail somites (Fig. 3E). Finally, from
14.5 dpc expression down-regulates (Fig. 3F), and it is
abolished in all sites of normal Myf5 expression in adult
muscle (data not shown).
The unexpected fact that Myf5 is widely expressed in
the absence of its functionally defined minimal pro-
moter means that the locus must contain at least one
other, cryptic, promoter, and that many of the enhancers
can activate it. This raises the question of whether the
enhancers can engage with such sequences even when
the minimal promoter is present. Moreover, it is clear
that some of the enhancers that can activate the cryptic
promoter—e.g., arch and limb enhancers—also activate
the Mrf4 promoter in the same cell population at the
same time, and are thus not making a simple competi-
tive choice. We suggest that they participate in an equi-
librium system in which they can engage with multiple
other sequences within a short time period. It is again
noteworthy that the EEE cannot activate the cryptic pro-
moters in this context, nor can the element that nor-
mally maintains Myf5 expression after 14.5 dpc.
Modification or deletion of the Myf5 minimal
promoter activates novel initiation sites in the locus
To map the cryptic promoter(s) we carried out 5!-RACE
on mRNA extracted from 13.5-dpc B195APZwt,
B195APZmTATA-5, and B195APZ!MP5 embryos. The
TATA-box mutation alters the initiation site, leading to
a variety of transcripts with 5!-ends ranging from −650 to
−100 bp relative to the translational start site, and very
little, if any, initiation at the normal site (Fig. 4A [lane 3],
B; Supplemental Fig. 1), indicating that this consensus
TATA box is responsible for specifying the transcrip-
tional start site of Myf5 and that, under normal develop-
mental conditions, its absence does not affect the expres-
sion pattern, while resulting in incorrect initiation. It
also follows that transcription initiated at upstream start
sites is correctly regulated by, as far as we can tell, all of
the enhancers. For B195APZ!MP5 the nlacZ-specific
nested primer set generates a ladder with fragments rang-
ing from 50 to 1200 bp (Fig. 4A [lane 4], B; Supplemental
Fig. 1), indicating that in the absence of the minimal
promoter several transcripts are generated, starting
within previously defined elements in the intergenic re-
gion: the proximal arch element (PAE), which in isola-
tion is able to drive arch expression from 9.5 dpc to 12.5
dpc, and the CNS element (CNSE), which drives expres-
sion in the neural tube (Summerbell et al. 2000). We
confirmed this using a different 5!-RACE protocol,
which generated similar results (TaKaRa protocol) (data
Figure 3. Myf5 expression is not abolished in the absence of its
minimal promoter. (A) nlacZ-Myf5 expression can be detected
at 9.5 dpc in the hyoid arch and the caudal edges of interlimb
somites (black and white arrowheads, respectively). (B) By 10.5
dpc, expression is up-regulated in the dermomyotome of cervi-
cal somites, the caudal lips of interlimb somites, and branchial
arches. (C) By 11.5 dpc, expression is clearly visible in fore- and
hindlimbs, and myotomal expression is up-regulated for the
first time. By 12.5 dpc (D), expression increases in all premuscle
masses, is maintained at 13.5 dpc (E), and then starts to down-
regulate at 14.5 dpc (F).
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not shown). Because of the nature of 5!-RACE protocols
we cannot rule out that some start sites are even further
upstream.
To confirm the existence of these new transcripts we
performed whole-mount in situ hybridization using a
probe corresponding to the CNSE. Transcripts are not
detected in nontransgenic (data not shown) or B195APZwt
embryos (Fig. 4C), but transcripts containing this
upstream sequence are detected in 10.5-dpc
B195APZmTATA-5 embryos (Fig. 4D), in the somites and
limbs and very faintly in the branchial arches (Fig. 4E,F).
Transcripts containing CNSE sequences are also de-
tected in 10.5- and 11.5-dpc B195APZ!MP5 embryos. At
10.5 dpc these transcripts are detected at low intensity in
hyoid arch, somites, and limb buds (data not shown),
while at 11.5 dpc transcripts are detected mainly in the
dorsal somites (Fig. 4G,H). The low intensity of the sig-
nals indicates that deletion of the promoter reduces the
levels of Myf5 transcription. Indeed, hybridization of
B195APZ!MP5 embryos using an nlacZ-specific probe
(pNLAC) shows that there is a significant reduction in
transcription levels in all muscle precursors in early em-
bryos (Fig. 4I) when compared with transgene expression
in B195APZwt lines (Fig. 4J). At later stages (10.5 and 11.5
dpc) (Fig. 4K,L, respectively), there is an increase in
nlacZ-Myf5 expression levels, particularly in derivatives
of the hyoid arch, recapitulating some of the differences
in intensity observed with "-galactosidase staining of
these lines (Fig. 3B). The novel transcripts are found only
where Myf5 is normally expressed; we saw no evidence
for inappropriate expression.
The Mrf4 promoter is a key element
in the maintenance of equilibria in the locus
We next generated a construct in which the Mrf4 mini-
mal promoter (as functionally defined by Black et al.
1995; see Supplemental Fig. 2) was deleted
(B195APZ!MP4) (Fig. 1G). TheMyf5 expression pattern in
such embryos (Fig. 5A) is indistinguishable from that of
B195APZwt embryos (Fig. 6A), while AP-Mrf4 expression
is completely abolished (data not shown), suggesting that
all the cryptic promoters in the locus are located in the
intergenic region. Because in the absence of the Myf5
minimal promoter some of the Myf5-specific enhancers
are able to drive both nlacZ-Myf5 and AP-Mrf4 expres-
sion, we generated construct B195APZ!MP4/!MP5 (Fig.
1H), in which both promoters are absent, to ascertain if
the nlacZ-Myf5 expression was a result of read-through
from the Mrf4 promoter. At 9.5 dpc, construct
B195APZ!MP4/!MP5 drives nlacZ-Myf5 expression in the
dermomyotome and branchial arches but fails to drive
dorsomedial lip or myotomal expression (Fig. 5B), show-
ing that in the absence of the Myf5 minimal promoter
nlacZ-Myf5 does not initiate at theMrf4 promoter. More
importantly, comparison of the nlacZ-Myf5 expression
patterns of B195APZ!MP4/!MP5 and B195APZ!MP5 in the
somites (Fig. 5B,C, respectively) shows that theMrf4 pro-
moter prevents a somitic enhancer from activating
the cryptic promoters at this time, and only by removing
the Mrf4 promoter is the enhancer able to drive nlacZ-
Myf5 in the dermomyotome. We infer that the enhancer
preferentially interacts nonproductively with the Mrf4
Figure 4. Alterations in the composition of the
locus result in modifications of the transcrip-
tional start site ofMyf5 as detected by 5!-RACE
and in situ hybridization. The transcriptional
start sites for the transgene change depending
on the promoter/enhancer composition of the
locus. Mutation of the TATA box in the Myf5
promoter results in the activation of multiple
transcription initiation sites. (A) Deletion of the
Myf5 minimal promoter, which activates a
cryptic promoter, also results in multiple tran-
scriptional starts, while deletion of the PAE or
the Mrf4 promoter has a strong influence on
transcription initiation atMyf5, resulting in the
activation of additional cryptic sites. (Lane 1)
One-kilobase DNA marker (GIBCO-BRL). (Lane
2) Wild type. (Lane 3) B195APZmTATA-5. (Lane 4)
B195APZ!MP5. (Lane 5) B195APZ!PAE. (Lane 6)
B195APZ!PAE/!MP5. (Lane 7) B195APZ!MP4.
These putative initiation sites are represented
in B, and have been shown to map to different
enhancer elements upstream of the Myf5 pro-
moter. These transcripts can be detected by us-
ing riboprobes against noncoding sequences im-
mediately upstream of the promoter (D–H), but
not in B195APZwt embryos (C). Hybridization
with a nlacZ-specific riboprobe shows low over-
all levels of transgene transcription (I,K,L) com-
pared with a transgenic line carrying the wild-
type BAC (J).
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promoter when it is present. There is no expression in
the dorsomedial lip, confirming that even if the Myf5
minimal promoter is not present the EEE is sequestered
by other sequences and prevented from activating the
Mrf4 promoter (see model in Fig. 7B). At later stages the
double deletion results in up-regulation of nlacZ-Myf5 in
all muscle precursors (Fig. 5D) when compared with
B195APZ!MP5 (Fig. 5E), and the pattern became indis-
tinguishable from that driven by B195APZwt (Fig. 5F).
This shows that most, if not all, of the enhancers can
activate the cryptic promoters if the Mrf4 promoter is
absent. Surprisingly, this deletion alters the Myf5 initia-
tion site, activating a site within the CNSE, and minor
sites within the PAE in addition to the normal site (Fig.
4A [lane 7], B). The finding that deletion of the Mrf4
promoter affects transcriptional initiation at Myf5 indi-
cates that both promoters are part of an equilibrium op-
erating in the locus.
The PAE is in equilibrium with other enhancers
in the locus and with the Mrf4 minimal promoter
Expression in the branchial arches is subject to probably
the most complex regulatory system in the locus, with at
least five enhancers acting in the arches and their deriva-
tives (Summerbell et al. 2000; Carvajal et al. 2001). Fur-
thermore, we showed that in the absence of the Myf5
minimal promoter, nlacZ-Myf5 expression in the hyoid
arch is maintained or up-regulated at the transcriptional
level, suggesting that the PAE strongly activates the
cryptic promoters in the locus. To investigate this and
the contribution of the PAE to the normal regulation
of Myf5, we analyzed nlacZ-Myf5 expression in
B195APZ!PAE embryos, in which the PAE had been de-
leted (Fig. 1E; Supplemental Fig. 1). Early Myf5 arch ex-
pression was normal, but was down-regulated from 9.5
dpc (data not shown), although not completely abol-
ished. We could not detect any other effects at any of the
stages analyzed (9.5–13.5 dpc) (data not shown), indicat-
ing that sequences within the PAE are not required to
Figure 6. The PAE is essential for the maintenance of the equi-
librium between enhancers and promoters in the locus. nlacZ-
Myf5 expression patterns driven by B195APZwt (A) and
B195!MP5 (B) constructs at 9.5 dpc. (C) Deletion of both theMyf5
minimal promoter and the PAE results in the rescue of the
complete pattern of expression at this stage. (D) Single PAE
deletion results in the loss of arch expression at 11.5 dpc, with-
out any other effects on Myf5 expression. Double PAE/MP5
deletion abolishes AP-Mrf4 expression in the arches (E), which
is readily detected in the single MP5 deletion (F). Single PAE
deletion alters the expression of Mrf4 (G) by activating Myf5-
specific expression in the brain (H) and early in the limbs (I).
Figure 5. The Mrf4 promoter is a key player in the enhancer–
promoter equilibria in the locus. Deletion of the Mrf4 minimal
promoter does not affect the nlacZ-Myf5 expression pattern (A),
while the double MP4/MP5 deletion partially rescues the early
(9.5 dpc) Myf5 expression pattern (B), lost in the single MP5
deletion (C). The double deletion also rescues the expression
pattern at 11.5 dpc, resulting in up-regulation of the transgene
in all premuscle masses (D), while the construct carrying the
single MP5 deletion is unable to drive full expression in limbs,
interlimb, or tail somites (E). (F) The B195APZ!MP4/!MP5 expres-
sion pattern is indistinguishable from that of B195APZwt at this
stage.
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activate Myf5 transcription at any other location. Sur-
prisingly, deletion of the PAE alone results in the acti-
vation of an upstream start site, while the normal site
downstream from the TATA box remains active (Fig. 4A
[lane 5], B). The changes in the transcriptional start site
of Myf5 in the absence of the PAE indicate that it has
dual functions, to drive late arch expression and to en-
sure correct transcriptional initiation at the minimal
promoter.
Our data suggest that sequences within the PAE may
contribute to the regulation of the equilibria within the
locus, and we showed that the EEE is subject to particu-
larly stringent regulation. To further explore the role of
the PAE we analyzed B195APZ!PAE/!MP5 animals, lack-
ing both the Myf5 minimal promoter and the PAE (Fig.
1F). To our surprise, the fullMyf5 expression pattern was
restored at 9.5 dpc (Fig. 6C), including expression in the
dorsomedial lip of the somite, driven by the EEE (Sum-
merbell et al. 2000; Teboul et al. 2002). The pattern was
indistinguishable from that of B195APZwt (Fig. 6A),
showing that the enhancers accurately regulate the cryp-
tic promoters. Deletion of both the PAE and the Myf5
minimal promoter allows the EEE to activate the other
cryptic promoters to drive correct dorsomedial lip Myf5
expression. The simplest explanation of these data is
that in the absence of the Myf5 minimal promoter the
EEE interacts with sequences within the PAE interval in
a way that prevents it from activating the cryptic pro-
moters (see model in Fig. 7A–C).
By 11.5 dpc,Myf5 arch expression is down-regulated in
B195APZ!PAE/!MP5 embryos (data not shown), reproduc-
ing the timing of arch expression driven by construct
B195APZ!PAE (Fig. 6D). Because the down-regulation
of Myf5 arch expression in B195APZ!PAE overlaps in
time with the up-regulation of Mrf4 expression in
B195APZ!MP5 lines, we hypothesized that in the ab-
sence of the Myf5 minimal promoter the PAE engages
with the Mrf4 minimal promoter to drive this expres-
sion. Analyses of the AP-Mrf4 expression pattern at 11.5
dpc in B195APZ!PAE/!MP5 embryos (Fig. 6E) show that
this is indeed the case, as these embryos lack the arch
expression seen in B195APZ!MP5 embryos (Fig. 6F),
while the remainder of the pattern was identical (data
not shown). In the absence of both the PAE and the mini-
mal promoter, transcription is still initiated within the
CNSE and at locations upstream of the deleted PAE (Fig.
4A [lane 6], B), indicating that a variety of sequences in
the locus are able to initiate transcription in the absence
of the minimal promoter.
We showed that the PAE has a dual function, control-
ling the expression of Myf5 in the branchial arches and
ensuring correct transcriptional initiation at the Myf5
promoter. In the absence of the Myf5 minimal promoter
the PAE is involved in driving expression of AP-Mrf4 in
Figure 7. Schematic representation of the transcriptional equi-
libria in the Mrf4/Myf5 locus. The equilibria between the tran-
scriptional elements in the locus control promoter–enhancer
specificity in different ways depending on the enhancer re-
quired. (A–C) Early epaxial enhancer. In the wild-type situation,
the equilibrium between the EEE and the other elements in the
locus is displaced toward the Myf5 minimal promoter, which
results in the only possible productive interaction. (B) Deletion
of the Myf5 minimal promoter distorts the equilibrium, but
none of the interactions are productive. (C) This distortion is
detected when both the PAE and the Myf5 minimal promoter
are removed, and the EEE can activate transcription from the
TRABS but not from the Mrf4 promoter. (D–F) Brain and limb
elements. (D) As with the EEE, in the wild-type situation the
equilibrium is displaced toward the activation of theMyf5mini-
mal promoter. (E) Removal of this element results in the total
reversion of the equilibrium generating productive interactions
with the Mrf4 promoter and the TRABS in the locus. (F) Re-
moval of a single TRABS (the one within the PAE interval)
without modifying the promoter composition of the locus also
results in reversion of the equilibrium, and these enhancers
activate transcription at the Mrf4 and Myf5 promoters and at
other TRABS. (G–H) Proximal arch element. (G) As in the other
cases, in the wild-type situation the equilibrium favors the ac-
tivation of theMyf5 promoter as a result of the only productive
interaction. (H) Deletion of the promoter unbalances the equi-
librium, making the different interactions productive. Arrows
indicate the direction of the equilibria, while thickness indi-
cates the favored state. Deleted elements are represented in
gray. Dotted arrows indicate that the interaction of the EEE
with the Mrf4 promoter, which we have not detected to date,
may not form part of this equilibrium. Dark and pale orange
represent productive and nonproductive states, respectively. In-
teraction and bending of the DNA is only used as a representa-
tion, and should not be taken as an indication of mechanism.
We diagrammed only some of the possible interactions in order
to exemplify the principles of our model.
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the arches while double deletion of the PAE and the
Myf5 minimal promoter reveals that sequences within
the PAE interval sequester some Myf5-specific enhanc-
ers, thus preventing their interaction with other cryptic
promoters in the locus. If the role of the PAE interval in
the maintenance of the equilibria is crucial, deletion of
this element in isolation should result in alteration of
the enhancer–promoter specificity in the locus. While
the changes in the pattern of nlacZ-Myf5 are restricted to
the absence of early arch expression (Fig. 6D), there are
important changes to the AP-Mrf4 pattern (Fig. 6G),
which incorporates expression in the brain (Fig. 6H) and
the limb buds (Fig. 6I). Therefore, in the absence of the
PAE at least some enhancers are able to activate basal
promoters that they cannot access when it is present,
indicating that sequences within the PAE interval play a
key role in regulating the overall enhancer–promoter
equilibria (see model in Fig. 7D–H).
Discussion
Promoter–enhancer equilibria
Eukaryotes employ many different mechanisms to en-
sure that transcriptional units can respond appropriately
to the surrounding environment in order to regulate the
activity levels of the many proteins encoded in their ge-
nomes. Crucial to this response is the control of tran-
scriptional regulators themselves, as downstream gene
activation is mainly dependent on the correct control of
transcription factor activity. In multicellular organisms
complex regulatory mechanisms are required to ensure
tight regulation of tissue-specific gene expression. These
mechanisms must be even more complex when two or
more genes, with distinct expression patterns, are linked
in the genome, with the possibility of enhancer cross-
talk even greater. Furthermore, it has been shown that
gene duplication is usually accompanied by the sharing
of enhancers belonging to the protogene, and the special-
ization of the duplicated genes for individual enhancers,
usually resulting in nonoverlapping patterns that when
combined cover the entire expression pattern of the
original gene (Bruce et al. 2001; Locascio et al. 2002; de
Souza et al. 2005). We propose that the regulation of such
loci involves additional mechanisms to ensure the cor-
rect enhancer–promoter specificity.
In multigene loci, several mechanisms have been de-
scribed to explain how promoter–enhancer specificity is
established. These seem to rely on a hierarchical archi-
tecture in which promoters compete for the different en-
hancers, with sequences either within (TATA box,
downstream promoter elements, initiator sequences) or
outside (tethering elements) the promoters used to
modify the strength of the competition, and/or block
such interactions (silencers, insulators, boundary ele-
ments). Other elements involved are the LCRs, respon-
sible for the initiation and/or maintenance of tissue-spe-
cific gene expression. The most widely studied LCR is
that of the !-globin gene cluster, which has been shown
to be required for high levels of !-globin expression (for
reviews, see Fraser and Grosveld 1998; Li et al. 2002).
Importantly, the individual globin genes compete for the
LCR and, as with other forms of promoter competition,
the LCR only interacts with one promoter at a time
(Wijgerde et al. 1995). Finally, another cis-regulatory el-
ement, the promoter targeting sequence, has also been
shown to contribute to promoter–enhancer specificity by
selectively bypassing the effects of specific insulators in
the Drosophila Abd-B gene (Zhou and Levine 1999).
By altering the regulatory element composition of the
Mrf4/Myf5 locus we now reveal a new mechanism. In
the absence of the Myf5 minimal promoter, some of the
enhancers that interact with it in the normal context are
recruited by the Mrf4 promoter to drive Myf5-specific
expression. Strikingly, other sequences in the locus can
also recruit these enhancers and assemble the transcrip-
tional machinery to drive Myf5 expression in the ab-
sence of its promoter. Not all of the enhancers behave in
the same manner, and thus, for example, expression is
up-regulated in the hyoid arch at 9.5 dpc and myotomal
expression is down-regulated at early stages, while dor-
somedial lip expression mediated by the EEE is com-
pletely abolished. Because some of the enhancers drive
expression of both AP-Mrf4 and nlacZ-Myf5 in the same
location and at the same stage, this novel mechanism
does not correspond to any previously described on/off-
switch model. Deletion of the Mrf4 minimal promoter
alters the expression of Myf5 at two time points during
development. Early Myf5 expression is missing in the
somitic bud, and late expression is abolished throughout
the embryo and in the adult. Even more intriguingly, the
deletion of both the PAE and the Myf5 minimal pro-
moter results in pattern reversion of Myf5 expression to
that of the wild type. Analyses at the RNA level indicate
that deletion of either promoter results in modifications
to the transcriptional start site for nlacZ-Myf5, further
evidence of the cis-regulatory interactions between the
two promoters in the locus. But these alterations in tran-
scription initiation are not restricted to constructs miss-
ing the natural promoters. Indeed, deletion of the PAE
also results in alteration of transcriptional initiation and
changes in the pattern of Mrf4 expression. These obser-
vations indicate that the locus is not regulated by
straightforward promoter competition, and that ele-
ments different from the core promoters are involved in
enhancer–promoter selectivity, elements that we name
TRABS.
Cryptic promoters or TRABS
The term cryptic promoter is commonly used in the lit-
erature to refer to a fragment of genomic DNA that is
able to act as a promoter in certain circumstances but
does not normally act. In this way, in several chromo-
somal translocations involving the c-myc locus, and giv-
ing rise to mouse plasmacytomas, it has been shown that
the loss of the endogenous c-myc promoter in the deriva-
tive chromosome does not imply the silencing of c-myc,
and that the generation of a truncated c-myc protein is
due to the activation of bipolar cryptic promoters in the
locus (Calabi and Neuberger 1985; Murphy et al. 1986). A
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cryptic promoter located 2 kb upstream of the Slp gene in
the eIF4G locus, and originally defined as an internal
ribosomal entry site (IRES), has been recently shown to
be able to increase by 850 times the expression of an
associated Renilla luciferase gene (Han and Zhang 2002).
The authors also identified additional cryptic promoters
in the 5!-untranslated region (UTR) of the Bad and Sno
genes, previously defined as IRES, and concluded that
cryptic promoter activities in the 5!-UTR sequences of
cellular mRNAs are more prevalent than anticipated.
Deletion of theMyf5minimal promoter in the context
of B195APZ results in the activation of a cryptic pro-
moter(s) in the locus. Furthermore, we showed that de-
letion of a single enhancer (the PAE) is enough to acti-
vate a cryptic promoter, as revealed by 5!-RACE analy-
ses. It is not clear at the moment if these sequences are
one or many, although the variation in the transcrip-
tional start site for the nlacZ-Myf5 transgene in the dif-
ferent deletion constructs indicates that multiple se-
quences in the locus may be activated as cryptic promot-
ers. Furthermore, we showed that the cryptic promoters
are able to engage with most of the Myf5-specific en-
hancers in a context-dependent manner, changing their
specificity according to the promoters in the locus, sug-
gesting that the different sequences are in competition
with the natural promoters and with each other. We pro-
pose that many of the sequences described as cryptic
promoters in the literature are in fact TRABS, and that
their function is to establish an equilibrium with the
promoter(s) in the locus to ensure the fine control of the
interactions between enhancers and natural promoters
required for the correct transcriptional initiation of gene
expression.
Analysis of the equilibrium
Deletion of the Myf5 minimal promoter leads to Mrf4
expression in a number of sites (brain, branchial arches,
and limbs) that are normallyMyf5-specific, which might
be taken as indicating that for some enhancers there is
straightforward promoter competition. However, other
enhancers, most notably the EEE, cannot engage with
the Mrf4 promoter even when the Myf5 promoter is ab-
sent, indicating that a different mechanism must oper-
ate. Many of the enhancers can thus engage with the
cryptic promoters in an entirely specific fashion, but
their ability to do so is modulated not only by the Myf5
promoter, which would be expected, but also by theMrf4
promoter and the PAE. A key feature of the model that
we propose (Fig. 7) is that these interactions between the
enhancers and the cryptic promoters occur normally
(Fig. 7A,D,G), and that they dynamically regulate the
choices made as to which enhancers should engage with
which promoter, in which progenitor cell population and
at what time.
The second key observation is that in the absence of
the Myf5 minimal promoter, enhancers operating in the
arches (Fig. 7H), the limbs or the brain (Fig. 7E), engage
with both the Mrf4 promoter and the cryptic promoters
in the same progenitor cell population at the same time.
It is clear that the ways in which the enhancers engage
with the promoters are not controlled by an on/off
switch. Rather, we propose that the enhancers are con-
tinuously interacting with a number of transcription ini-
tiation sites in the locus, and which interaction leads to
the productive initiation of transcription is dictated by the
instructive signals that the progenitor cell is receiving.
The model is further supported by the deletion of the
minimal promoters of both Mrf4 and Myf5. While most
of the early Myf5 somitic pattern is abolished in the ab-
sence of the Myf5 minimal promoter, deletion of the
Mrf4 promoter results in partial rescue of the somitic
pattern. We suggest that the enhancer driving this ex-
pression cannot engage with the cryptic promoters be-
cause it is sequestered nonproductively by the Mrf4 pro-
moter. When the latter is removed, the enhancer is re-
leased and engages productively with the cryptic
promoters. Similarly, the EEE cannot activate the cryptic
promoters in this context because it is sequestered by
sequences within the PAE interval. This is a third key
feature of our model, the regulation of the locus depends
on interactions between enhancers and promoters, both
conventional and cryptic, that do not lead to the initia-
tion of transcription.
It is striking that in our initial experiments the EEE
was not seen to interact with anything other than the
Myf5 minimal promoter, implying that there must be a
mechanism that prevents its engagement with the Mrf4
and cryptic promoters (Fig. 7B). But deletion of the PAE
and the Myf5 minimal promoter allows the EEE to acti-
vate one or more cryptic promoters (Fig. 7C). We thus
infer that the EEE normally engages productively only
with the Myf5 minimal promoter but that it is in an
equilibrium between that promoter and the TRABS
within the PAE interval. Only when both are removed is
the EEE able to activate the cryptic promoters, although
it is still, by an unknown mechanism, prevented from
activating theMrf4 promoter. It is important to mention
that is not clear yet if the PAE interval contains two
separable functional elements (the arch enhancer and the
TRABS) or if they are interdigitated or even synony-
mous, and we are currently investigating this point. We
suspect that if all the TRABS were removed, then the
EEE would be able to activate theMrf4 promoter, and we
are examining this issue.
The Mrf4 ‘knockout’ and the Myf5 ‘knock-in’ revisited
Three different Mrf4 knockout alleles were generated
more than a decade ago by the laboratories of Arnold,
Olson, and Wold (for review, see Olson et al. 1996 and
references therein). Although all three alleles abolished
Mrf4 expression, variable cis-acting effects on the linked
Myf5 gene were observed, resulting in homozygous phe-
notypes ranging from full viability to complete lethality.
In a previous article (Olson et al. 1996), we and others
hypothesized that the presence of the strong pgk pro-
moter on the selectable marker was partially responsible
for some of the cis-effects observed, but we did not have
an explanation for the mechanism or for the apparent
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discrepancy in phenotypes between the two alleles
where the construction of the targeted allele was very
similar but the resulting phenotypes widely different.
The Olson allele, in which the pgk-neo-selectable
marker is transcribed in the opposite direction to Mrf4
and Myf5, presented the mildest of phenotypes, with
some rib malformations and no overt problems with
myogenesis. The Arnold and Wold alleles carried the
pgk-neo-selectable marker in the same orientation as
Mrf4 and Myf5, and while both presented myogenic de-
fects, some animals carrying the Wold allele survived to
adulthood while none of the animals carrying the Arnold
mutation survived after birth.
The work presented here readily explains these results
in that the presence of the strong pgk promoter would
alter the transcriptional equilibria in the locus by com-
peting with the endogenous promoters and TRABS, re-
sulting in the misregulation ofMyf5. Furthermore, in the
Arnold allele, which resulted in a double Mrf4/Myf5
knockout, 102 bp of the Mrf4 minimal promoter were
crucially removed, including the transcriptional start
site (Braun and Arnold 1995). As we showed that the
Mrf4minimal promoter is a major player in establishing/
maintaining the equilibria in the locus and is essential to
determine the correct transcriptional initiation site for
Myf5, it is likely that even its partial removal compro-
mises Myf5 promoter function, as we showed with our
B195APZ!MP4 lines, in which Myf5 expression in the
somitic bud, late embryonic phases and the adult is abol-
ished. Thus, the combination of the partial promoter de-
letion and the inclusion of an additional promoter in the
locus could have resulted in the complete down-regula-
tion of the linked Myf5 gene, resulting in the double
knockout characteristic of this allele.
More recently, Kassar-Duchossoy et al. (2004) have
shown other cis-effects in the locus in a series of Myf5
knock-in lines. The original Myf5nlacZ allele (Tajbakhsh
et al. 1996a) and two new alleles, Myf5GFP-P and
Myf5loxP, show differential effects on the levels of
Mrf4. Expression of Mrf4 is abolished at 10.5 dpc in
Myf5nlacZ/nlacZ embryos, and reduced to half of the nor-
mal levels inMyf5nlacZ/+ littermates. A similar knock-in
allele, Myf5GFP-P also shows alteration in Mrf4 levels, in
both heterozygous and homozygous animals, but this ex-
pression is not completely abolished. Finally, in
Myf5loxP/loxP embryos, cis-effects were not observed. Al-
though the three alleles abolish functional Myf5 protein
and have similar genomic structures, the selectable
markers and associated promoters used are different. In
the Myf5nlacZ allele, the neo cassette is driven by the
RNA pol II promoter (Tajbakhsh et al. 1996b), while in
the Myf5GFP-P allele the puromycin cassette is driven by
the pgk promoter (Kassar-Duchossoy et al. 2004). It is
therefore possible to speculate that the phenotypes of
these two alleles that introduce a foreign promoter into
the locus are due to their ability to disrupt the delicate
balance required to set the enhancer–promoter specific-
ity. Differences in phenotypes between these two alleles
would be caused by the different affinities of the foreign
promoters for the existing transcriptional elements in
the locus. Furthermore, Kaul et al. (2000) have shown
that the rib phenotype observed in two of the original
Myf5 knockout alleles is caused by the selectable
marker, although in this case the mechanism is unclear.
Conclusion
There are now a number of examples of genes with regu-
latory elements located far from the promoter, and it is
noteworthy that they tend to encode either signaling
molecules (e.g., Shh) or transcription factors (e.g., Sox9)
involved in the control of cell fate decisions (Sagai et al.
2005; Bien-Willner et al. 2007). The extremely compli-
cated enhancer organization in the Mrf4/Myf5 locus is
also not unique. Sox2 is expressed throughout the early
nervous system, but this overall expression pattern is the
summation of the activities of a number of dispersed
enhancers, each of which operates in a particular popu-
lation of progenitor cells at a particular time (Uchikawa
et al. 2003). Structuring the regulatory elements in this
way, together with the novel regulatory mechanism de-
scribed here, would seem to be particularly appropriate
for genes encoding transcription factors, like Myf5 and
Sox2, which determine cell fate and have to be induced
widely in the embryo in response to a variety of induc-
tive signals.
Our data lead to a model that is quite distinct from
those developed from analyses of the "-globin and Hox
loci. They imply that the enhancers operate in what
might be thought of as a neural network model. They are
continuously interacting with not only the two conven-
tional promoters in the locus but also with a number of
sequences that can act as cryptic promoters, which we
call TRABS. These interactions must be modulated by
the inductive signals that determine skeletal muscle
identity and lead to the activation of the two genes in an
exquisite temporal and spatial pattern involving many
different progenitor cell populations at many stages of
development.
Materials and methods
Homologous recombination in Escherichia coli
Details on the construction of modifying cassettes can be found
in the Supplemental Material.
We used the linear recombination method (Swaminathan et
al. 2001) with some modifications. BAC clones were transferred
into DY380 cells (kindly provided by Neil Copeland, National
Cancer Institute-Frederick, Frederick, Maryland), which carry
the temperature-inducible #-recombinase system.
Single DY380 colonies carrying the desired BAC clone were
isolated and grown overnight at 32°C. Two-hundred-twenty mi-
croliters of these cultures were used to seed 11 mL of LB and
were incubated at 32°C with vigorous shaking (>300 rpm) until
OD600 was 0.6 ± 0.05. Cultures were then transferred to a 42°C
waterbath and incubated for 15 min. Cultures were transferred
to ice, incubated for 20 min, made electrocompetent by stan-
dard methods, and resuspended in a final volume of 30 µL.
Modifying cassettes (2 nmol for TATA box mutation; 1 µg for
other cassettes) were denatured, ethanol-precipitated, and re-
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suspended in 20 µL of ice-cold H2O. The denatured cassettes
were mixed with 30 µL of electrocompetent DY380 cells carry-
ing the BAC clone to be modified. Electroporations were carried
out using the Bio-Rad GenePulser II system (1.75 kV, 100 !, 25
µF). Electroporated cells were diluted 1:106 into a final volume
of 50 mL of LB and aliquoted into a single 96-well plate (500 µL
per well), resulting in an average of 20–50 cells per well. After
overnight incubation at 32°C, pools were screened using the
appropriate primers (see the Supplemental Material). Two to six
positive pools were plated to obtain single colonies, and a sec-
ond round of screening was carried out to identify single posi-
tives. Clones were sequenced using primers outside the homol-
ogy arms.
Generation of transgenic mice
All in vivo experimentation was performed according to United
Kingdom Home Office Regulations. BAC DNA was prepared
using the QIAgen Maxiprep kit (Qiagen) as described previously
(Carvajal et al. 2001). After dialysis against microinjection
buffer (10 mM Tris-HCl at pH 7.5, 0.1 mM EDTA at pH 8.0, 100
mM NaCl), DNA was diluted to 1.5 ng/mL in microinjection
buffer and used to inject fertilized mouse eggs from CBA/
Ca × C57Bl/6 crosses, as described previously (Yee and Rigby
1993).
Histochemical staining
"-Galactosidase: Embryos were fixed overnight in Mirsky’s fixa-
tive (National Diagnostics) at 4°C, washed three times in PBSA
(Ca2+, Mg2+-free phosphate-buffered saline)/0.02%Nonidet P-40
for 20 min at room temperature, placed in 10 mL of X-gal solu-
tion [5 mM K3Fe(CN)6, 5 mM K4Fe(CN)6 # 3H2O, 2 mM MgCl2,
0.02% Nonidet P-40, 0.4 mg/mL X-Gal in PBSA] for 2–20 h
(depending on stage) at 37°C, and post-fixed inMirsky’s fixative.
Alkaline phosphatase: Embryos were fixed in 4% paraformal-
dehyde in PBSA overnight at 4°C, rinsed twice in PBSA + 2 mM
MgCl2, and washed in PBSA + 2 mM MgCl2 for 10 min. Endog-
enous phosphatases were inactivated by incubation for 1 h in
PBSA + 2 mM MgCl2 at 65°C. Embryos were equilibrated in
AP-buffer (100 mM Tris-HCl at pH 9.5, 100 mM NaCl, 50 mM
MgCl2, 0.1% Tween 20). Embryos were washed once in ice-cold
AP-buffer, transferred to AP-staining buffer (AP-buffer + 0.1
mg/mL of BCIP; 0.5 mg/mL NBT), and stained for 3–10 h (de-
pending on stage) in the dark at 4°C. The reaction was stopped
by washing in ice-cold PBSA containing 2 mM EDTA in the
dark for 24 h at 4°C. Embryos were post-fixed in Mirsky’s fixa-
tive adjusted to pH 5.0.
RACE
Embryos were obtained from timed matings, taking the day of
vaginal plug as 0.5 dpc, and dissected in PBSA. For the identi-
fication of transgenic embryos, left forelimbs were transferred
to single tubes containing 1 mL of X-gal solution (see above) and
incubated at 37°C until coloration was detected. Single 13.5-dpc
embryos were homogenized in 1 mL of TRI reagent (Sigma)
using disposable plastic pestles and RNA isolated following the
manufacturer’s recommendations. RNA was resuspended in a
final volume of 500 µL of DEPC-treated H2O. We used the
SMART RACE Amplification Kit (BD Biosciences) following
manufacturer’s recommendations. Single-stranded cDNA was
amplified by PCR using the Advantage 2 PCR Kit (BD Biosci-
ences) using eitherMyf5- or nlacZ-specific primers (Supplemen-
tal Material). Single amplification bands were gel-purified and
cloned into pCR-TOPO (Invitrogene) for sequencing.
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